Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2019-11-11 Earnings Release
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
Results for Bimagrumab in Obesity and Type 2 Diabetes presented by MorphoSys's Partner (news with additional features)
Earnings Release Classification · 99% confidence The document is a 'News Details' announcement from MorphoSys AG, dated November 11, 2019, disseminated via DGAP-News (a service often used for regulatory or corporate news releases). The content primarily announces the presentation of Phase 2 clinical study results for a drug candidate (bimagrumab) by its partner, Novartis, at a medical conference (Obesity Week 2019). This is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal dividend/share change notice. It is an announcement of specific corporate/study progress. Since it is a news release detailing corporate events/results that doesn't fit the specific categories like ER (Earnings Release) or DIV (Dividend Notice), and it is not merely announcing the publication of a separate report (RPA), the most appropriate general category for a significant corporate update disseminated via a news service is Regulatory Filings (RNS), which serves as a broad category for such announcements not covered elsewhere. Q4 2019
2019-11-11 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Notification of Major Holdings' under German Securities Trading Act (WpHG) regulations. It details changes in voting rights percentages (from 7.28% to 7.94%) held by BlackRock, Inc. in MorphoSys AG. This content directly corresponds to the definition of a notification regarding changes in significant share ownership levels, which aligns best with the Major Shareholding Notification category (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the core content is the change in holding percentage, making MRQ more specific than DVA (Declaration of Voting Results) or RNS (General Regulatory Filing).
2019-11-11 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document explicitly states 'Directors’ Dealings' in the header and details transactions made by a 'person discharging managerial responsibilities' (Jens Holstein, Member of the managing body). This directly corresponds to the definition of Director's Dealing reports, which are classified under the code DIRS.
2019-11-07 English
MorphoSys to Present Data on Tafasitamab at ASH 2019 Meeting (news with additional features)
Regulatory Filings Classification · 100% confidence The document is a 'News Details' announcement from MorphoSys AG, dated November 6, 2019. The content explicitly states that the company will present data on its drug candidate, tafasitamab, at the upcoming American Society of Hematology (ASH) 2019 Annual Meeting. It details the abstracts accepted for presentation (clinical and preclinical data) and provides contact information. This is not a full financial report (like 10-K or IR), nor is it a transcript (CT) or a formal regulatory filing detailing financial results (ER/IR). It is an announcement about participation in a scientific/investor conference, which aligns best with an Investor Presentation (IP) or a general corporate announcement. Since it details specific data to be presented at a conference, 'Investor Presentation' (IP) is the most fitting category, as these announcements often precede or summarize the content of such presentations, even if the presentation itself is not fully attached here. Given the context of presenting scientific/clinical data to investors/the market, IP is chosen over the general fallback RNS.
2019-11-06 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed sections titled 'Notification of Major Holdings' which report changes in voting rights percentages (e.g., 6.75% new total) held by a legal entity (BlackRock, Inc.) in MorphoSys AG, referencing specific German securities law articles (Art. 40 WpHG, Sec. 33, 34 WpHG). This directly corresponds to the definition of reporting changes in significant share ownership levels, which maps to the 'Major Shareholding Notification' category (MRQ). Although it is a regulatory announcement disseminated via DGAP, the specific content is a major holding notification, making MRQ the most precise fit over the general RNS fallback.
2019-11-06 English
DGAP-DD: MorphoSys AG english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a section header 'Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them'. It details a transaction (Purchase of shares) by an individual named Jens Holstein, identified as a 'Member of the managing body'. This directly corresponds to the definition of Director's Dealing (insider trades) filings.
2019-11-06 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.